Amplia Therapeutics Company Description

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer.

It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.

Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Amplia Therapeutics Limited

Country	Australia
Founded	2000
Industry	Biotechnology
Sector	Healthcare
CEO	Christopher Burns

Contact Details

Address: 350 Queen Street Melbourne, 3000 Australia
Phone	61 3 9123 1140
Website	ampliatx.com

Stock Details

Ticker Symbol	INNMF
Exchange	OTCMKTS
Fiscal Year	April - March
Reporting Currency	AUD
ISIN Number	AU0000023822
SIC Code	2836

Key Executives

Name	Position
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.	Chief Executive Officer, MD and Director
Timothy Luscombe B.Com., C.A.	Chief Financial Officer
Rhiannon Jones B.Sc., Ph.D.	Chief Operating Officer
Dr. Jason Lickliter MBBS	Chief Medical Officer
Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD	Company Secretary